Walleye Capital
BLUE

Walleye Capital’s bluebird bio BLUE Stock Holding History

Walleye Capital’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-900
Closed -$57.2K – 4336
2023
Q1 		$57.2K Buy
+900
New +$103K ﹤0.01% 3165
2020
Q1 		– Sell
-100
Closed -$114K – 966
2019
Q4 		$114K Sell
100
-1,197
-92% -$1.3M 0.01% 1324
2019
Q3 		$1.54M Buy
1,297
+1,197
+1,197% +$1.83M 0.09% 300
2019
Q2 		$165K Sell
100
-201
-67% -$348K 0.02% 1044
2019
Q1 		$614K Buy
+301
New +$530K 0.1% 313

Other funds holding BLUE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Walleye Capital's BLUE Position: Q3 2024 in Review

Walleye Capital sold out of bluebird bio (BLUE) in Q3 2024, closing a stake of 16,706 shares — an estimated $329K sold.

Walleye Capital first reported a position in BLUE in Q3 2019 and held it in 9 quarters. The position peaked at $2.75M in Q2 2023. 140 funds tracked by Wall St. Rank hold BLUE as of Q3 2024.

  • Walleye Capital reported no remaining bluebird bio position as of Q3 2024 after selling out during the quarter.
  • Walleye Capital sold 16,706 bluebird bio shares in Q3 2024, an estimated $329K.
  • Walleye Capital first reported a position in bluebird bio in Q3 2019 and held it in 9 quarters.
  • Walleye Capital's bluebird bio position peaked at $2.75M in Q2 2023.
  • 140 funds tracked by Wall St. Rank held bluebird bio as of Q3 2024.

Based on Walleye Capital's 13F filing for Q3 2024, filed 14 Nov 2024.